Table 1.
Baseline Patient Demographics
| Full Cohort | MELD-Na >15 | MELD-Na 15 or less | p | ||
|---|---|---|---|---|---|
| N | 7922 | 3923 | 3999 | ||
| Age (Mean (SD)) | 55.06 (11.27) | 54.87 (11.09) | 55.24 (11.45) | 0.141 | |
| Gender (%) | Female | 3312 (41.9) | 1458 (37.2) | 1854 (46.5) | <0.001 |
| 0.052 | |||||
| White | 3219 (40.6) | 1640 (41.8) | 1579 (39.5) | ||
| Black | 1707 (21.5) | 848 (21.6) | 859 (21.5) | ||
| Race (%) | Hispanic | 1690 (21.3) | 827 (21.1) | 863 (21.6) | |
| Asian | 182 (2.3) | 76 (1.9) | 106 (2.7) | ||
| Other | 1124 (14.2) | 532 (13.6) | 592 (14.8] | ||
| <0.001 | |||||
| Medicare/Medicaid | 3381 (42.7) | 1730 (44.1) | 1651 (41.3) | ||
| Insurance (%) | Private | 2521 (31.8) | 1114 (29.7) | 1357 (33.9) | |
| Other | 2020 (25.5) | 1029 (26.2) | 991 (24.8) | ||
| Median days of follow up (IQR) | 823 (306–1461) | 580 (153–1218) | 976 (548–1706) | <0.001 | |
| Mean Elixhauser Comorbidity Index (SD) | 5.41 (3.24) | 6.53 (3.26) | 4.31 (2.82) | <0.001 | |
| MELD-Na | Median number of Measurements (IQR) | 4 (2–8) | 4 (2–10) | 4 (2–7) | <0.001 |
| during follow up | Average Minimum (S | 12.87 (6.95) | 17.05 (7.59) | 8.79 (2.32) | <0.001 |
| Average Maximum (SD) | 17.62 (9.15) | 25.30 (6.68) | 10.08 (2.71) | <0.001 | |
| MELD during follow up | Average Maximum (SD) | 16.36 (8.43) | 22.96 (7.17) | 9.92 (2.50) | <0.001 |
| Listed Patients | 998 (12.6) | 787 (20.1) | 211 (5.3) | <0.001 | |
| Median days on Waitlist (IQR) | 187 (26–1,208) | 113 (17–607) | 1916 (674–2557) | <0.001 | |
| Transplants | 440 (5.4) | 418 (10.7) | 22 (0.6) | <0.001 | |
| HCV | 38% | 35% | 41% | <0.001 | |
| HBV | 8% | 8% | 8% | 0.588 | |
| Etiology (%) | Alcohol | 45% | 59% | 32% | <0.001 |
| NASH | 19% | 18% | 19% | 0.177 | |
| Cholestatic | 10% | 9% | 11% | <0.001 | |
| Ascites | 41% | 64% | 18% | <0.001 | |
| HE | 37% | 58% | 16% | <0.001 | |
| Complications (%) | Varices | 34% | 43% | 26% | <0.001 |
| SBP | 8% | 14% | 1% | <0.001 | |
| HRS | 8% | 15% | 1% | <0.001 |